Current treatments for atrial fibrillation (AFib), a common heart condition characterized by fast and irregular beats that can lead to stroke and heart failure, have multiple side effects and are ineffective for preventing AFib recurrence.
PharmaSGP exceeds the € 100 million revenues mark in 2023 and plans further profitable growth in 2024 – Biotech Investments
EQS-News: PharmaSGP Holding SE / Key word(s): Preliminary Results/Forecast PharmaSGP exceeds the € 100 million revenues mark in 2023 and plans further profitable growth in